使 tisagenlecleucel

Juhong Jung1, Ju Hwan Kim1,2, Ji-Hwan Bae2

  • 1Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Republic of Korea.

Scientific reports
|June 13, 2024
PubMed
概括

化学抗原受体T细胞 (CAR-T) 疗法对血液癌症有前途,但可能导致心血管不良事件. 这项研究确定了tisagenlecleucel的六个潜在的心脏安全信号,敦促对患者进行仔细监测.